Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1

Not yet recruiting

Conditions: Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Non-Active Secondary Progressive Multiple Sclerosis
Non-Active SPMS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Demyelinating Diseases
Immune System Diseases

Interventions: Drug: IDP-023
Drug: Ocrelizumab
Drug: Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2024-11-07

Last Posted Date: 2025-01-07

Lead Sponsor: Indapta Therapeutics, INC.

Target Recruit Count: 34

Registration Number: NCT06677710

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1)

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus
Lupus Nephritis
Idiopathic Inflammatory Myopathies
Diffuse Cutaneous Systemic Sclerosis

Interventions: Biological: CNTY-101
Biological: IL-2
Drug: Lymphodepleting Chemotherapy

First Posted Date: 2024-02-12

Last Posted Date: 2025-01-09

Lead Sponsor: Century Therapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT06255028

Locations: 🇺🇸
Keck School of Medicine of University of Southern California, Los Angeles, California, United States
🇺🇸
Lurie Children's; Northwestern Medicine - Northwestern Medical Group, Chicago, Illinois, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 1 locations

CIML NK Cells With Venetoclax for AML

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia Recurrent
Leukemia, Myeloid
Leukemia

Interventions: Biological: Cytokine-Induced Memory-like Natural Killer Cells
Biological: Interleukin-2
Drug: Venetoclax

First Posted Date: 2023-12-01

Last Posted Date: 2024-12-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT06152809

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1

Recruiting

Conditions: Relapsed Multiple Myeloma
Multiple Myeloma
Blood Cancer
Relapsed Non-Hodgkin Lymphoma
Refractory Multiple Myeloma
NHL
Refractory Non-Hodgkin Lymphoma

Interventions: Drug: IDP-023
Drug: Cyclophosphamide
Drug: Daratumumab
Drug: Interleukin-2
Drug: Rituximab
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2023-11-07

Last Posted Date: 2025-01-10

Lead Sponsor: Indapta Therapeutics, INC.

Target Recruit Count: 128

Registration Number: NCT06119685

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States

and more 10 locations

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Early Phase 1

Not yet recruiting

Conditions: Solid Tumor

Interventions: Biological: Tumor Infiltrating Lymphocytes
Drug: Fludarabine
Drug: Cyclophosphamide Capsules
Drug: IL-2

First Posted Date: 2022-12-14

Last Posted Date: 2022-12-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT05649618

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Early Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Biological: TCR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide Capsules
Drug: Albumin-bound paclitaxel
Drug: IL-2

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-13

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05648994

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Platinum-resistant Ovarian Cancer
Post Anti-PD-1 Melanoma
2L+ Cervical Cancer
Neoadjuvant Melanoma
Neoadjuvant Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer

Interventions: Drug: TransCon IL-2 β/γ
Drug: Trastuzumab emtansine (T-DM1)
Drug: TransCon TLR7/8 Agonist
Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Chemotherapy drug
Procedure: Surgery

First Posted Date: 2021-10-18

Last Posted Date: 2025-01-08

Lead Sponsor: Ascendis Pharma Oncology Division A/S

Target Recruit Count: 473

Registration Number: NCT05081609

Locations: 🇨🇳
Ascendis Pharma Investigational Site, Taipei, Taiwan

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1

Recruiting

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human

Interventions: Drug: IL-2 (Aldesleukin)
Drug: Cyclophosphamide
Biological: KK-LC-1 TCR
Drug: Fludarabine

First Posted Date: 2021-09-05

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05035407

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Phase 2

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: IL-2

First Posted Date: 2021-07-07

Last Posted Date: 2021-08-18

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 13

Registration Number: NCT04952155

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Phase 1

Completed

Conditions: Recurrent Miscarriage

Interventions: Drug: low-dose IL-2

First Posted Date: 2019-06-03

Last Posted Date: 2024-05-14

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 18

Registration Number: NCT03970954

Locations: 🇫🇷
Mekinian, Paris, Hopital Saint Antoine, France
🇫🇷
Bornes, Paris, Hopital Tenon, France
🇫🇷
Kayem, Paris, Hopital Trousseau, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy